vs
MESA LABORATORIES INC（MLAB）与Resolute Holdings Management, Inc.（RHLD）财务数据对比。点击上方公司名可切换其他公司
Resolute Holdings Management, Inc.的季度营收约是MESA LABORATORIES INC的1.8倍（$117.7M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs -1.5%，领先7.0%），Resolute Holdings Management, Inc.自由现金流更多（$189.2M vs $18.0M）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业，核心业务布局于非洲地区，目前运营两座金矿，分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿，专注于黄金资源的勘探、开采及相关运营管理工作。
MLAB vs RHLD — 直观对比
营收规模更大
RHLD
是对方的1.8倍
$65.1M
净利率更高
MLAB
高出7.0%
-1.5%
自由现金流更多
RHLD
多$171.2M
$18.0M
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $117.7M |
| 净利润 | $3.6M | $-1.7M |
| 毛利率 | 64.2% | 55.7% |
| 营业利润率 | 12.2% | 30.2% |
| 净利率 | 5.6% | -1.5% |
| 营收同比 | 3.6% | — |
| 净利润同比 | 316.6% | — |
| 每股收益（稀释后） | $0.65 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABRHLD
| Q4 25 | $65.1M | $117.7M | ||
| Q3 25 | $60.7M | $120.9M | ||
| Q2 25 | $59.5M | $119.6M | ||
| Q1 25 | $62.1M | $103.9M | ||
| Q4 24 | $62.8M | — | ||
| Q3 24 | $57.8M | — | ||
| Q2 24 | $58.2M | — | ||
| Q1 24 | $58.9M | — |
净利润MLABRHLD
| Q4 25 | $3.6M | $-1.7M | ||
| Q3 25 | $2.5M | $-231.0K | ||
| Q2 25 | $4.7M | $-611.0K | ||
| Q1 25 | $-7.1M | $-3.4M | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $3.4M | — | ||
| Q2 24 | $3.4M | — | ||
| Q1 24 | $-254.6M | — |
毛利率MLABRHLD
| Q4 25 | 64.2% | 55.7% | ||
| Q3 25 | 61.5% | 59.0% | ||
| Q2 25 | 62.0% | 57.5% | ||
| Q1 25 | 61.8% | 52.5% | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
营业利润率MLABRHLD
| Q4 25 | 12.2% | 30.2% | ||
| Q3 25 | 7.8% | 34.3% | ||
| Q2 25 | 5.1% | 34.0% | ||
| Q1 25 | 2.4% | 24.7% | ||
| Q4 24 | 9.2% | — | ||
| Q3 24 | 6.1% | — | ||
| Q2 24 | 9.6% | — | ||
| Q1 24 | -460.6% | — |
净利率MLABRHLD
| Q4 25 | 5.6% | -1.5% | ||
| Q3 25 | 4.1% | -0.2% | ||
| Q2 25 | 8.0% | -0.5% | ||
| Q1 25 | -11.4% | -3.2% | ||
| Q4 24 | -2.7% | — | ||
| Q3 24 | 5.9% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | -432.2% | — |
每股收益（稀释后）MLABRHLD
| Q4 25 | $0.65 | $-0.20 | ||
| Q3 25 | $0.45 | $-0.03 | ||
| Q2 25 | $0.85 | $-0.07 | ||
| Q1 25 | $-1.30 | $-0.39 | ||
| Q4 24 | $-0.31 | — | ||
| Q3 24 | $0.63 | — | ||
| Q2 24 | $0.62 | — | ||
| Q1 24 | $-47.26 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $205.5M |
| 总债务越低越好 | $68.4M | $169.8M |
| 股东权益账面价值 | $186.7M | $6.5M |
| 总资产 | $434.8M | $333.4M |
| 负债/权益比越低杠杆越低 | 0.37× | 26.03× |
8季度趋势，按日历期对齐
现金及短期投资MLABRHLD
| Q4 25 | $29.0M | $205.5M | ||
| Q3 25 | $20.4M | $148.0M | ||
| Q2 25 | $21.3M | $99.9M | ||
| Q1 25 | $27.3M | $71.0M | ||
| Q4 24 | $27.3M | — | ||
| Q3 24 | $24.3M | — | ||
| Q2 24 | $28.5M | — | ||
| Q1 24 | $28.2M | — |
总债务MLABRHLD
| Q4 25 | $68.4M | $169.8M | ||
| Q3 25 | $69.4M | $173.4M | ||
| Q2 25 | $70.3M | $177.1M | ||
| Q1 25 | $71.3M | $180.7M | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABRHLD
| Q4 25 | $186.7M | $6.5M | ||
| Q3 25 | $178.5M | $10.8M | ||
| Q2 25 | $172.5M | $9.6M | ||
| Q1 25 | $159.8M | $8.9M | ||
| Q4 24 | $155.2M | — | ||
| Q3 24 | $161.5M | — | ||
| Q2 24 | $150.7M | — | ||
| Q1 24 | $145.4M | — |
总资产MLABRHLD
| Q4 25 | $434.8M | $333.4M | ||
| Q3 25 | $430.4M | $293.2M | ||
| Q2 25 | $435.7M | $253.3M | ||
| Q1 25 | $433.3M | $214.3M | ||
| Q4 24 | $433.3M | — | ||
| Q3 24 | $454.1M | — | ||
| Q2 24 | $440.4M | — | ||
| Q1 24 | $446.8M | — |
负债/权益比MLABRHLD
| Q4 25 | 0.37× | 26.03× | ||
| Q3 25 | 0.39× | 16.01× | ||
| Q2 25 | 0.41× | 18.42× | ||
| Q1 25 | 0.45× | 20.38× | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $189.2M |
| 自由现金流率自由现金流/营收 | 27.7% | 160.8% |
| 资本支出强度资本支出/营收 | 1.1% | 5.8% |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | $313.2M |
8季度趋势，按日历期对齐
经营现金流MLABRHLD
| Q4 25 | $18.8M | $196.1M | ||
| Q3 25 | $8.2M | $59.6M | ||
| Q2 25 | $1.9M | $48.9M | ||
| Q1 25 | $12.7M | $18.4M | ||
| Q4 24 | $18.1M | — | ||
| Q3 24 | $5.3M | — | ||
| Q2 24 | $10.7M | — | ||
| Q1 24 | $12.9M | — |
自由现金流MLABRHLD
| Q4 25 | $18.0M | $189.2M | ||
| Q3 25 | $7.1M | $58.6M | ||
| Q2 25 | $884.0K | $47.5M | ||
| Q1 25 | $11.9M | $17.8M | ||
| Q4 24 | $17.3M | — | ||
| Q3 24 | $3.5M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $12.3M | — |
自由现金流率MLABRHLD
| Q4 25 | 27.7% | 160.8% | ||
| Q3 25 | 11.7% | 48.5% | ||
| Q2 25 | 1.5% | 39.7% | ||
| Q1 25 | 19.2% | 17.1% | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | 16.9% | — | ||
| Q1 24 | 21.0% | — |
资本支出强度MLABRHLD
| Q4 25 | 1.1% | 5.8% | ||
| Q3 25 | 1.8% | 0.8% | ||
| Q2 25 | 1.7% | 1.2% | ||
| Q1 25 | 1.2% | 0.6% | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 0.9% | — |
现金转化率MLABRHLD
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
RHLD
暂无分部数据
